Streetbeat News

Earnings

TCRX

TScan Therapeutics (NASDAQ:TCRX) reported Q2 losses of $(0.51) per share, a 19.05% improvement from $(0.63) per share YoY. However, sales decreased by 22.39% to $3.15 million from $4.06 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:25 am

MNPR

Monopar Therapeutics reported Q2 losses of $(0.16) per share, a 27.27% improvement from $(0.22) per share YoY. The company's cash, cash equivalents and short-term investments of $10.2M are expected to fund operations through September 2024.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:24 am

WWW

Wolverine World Wide reported Q2 results and lowered its full-year outlook, causing its shares to trade lower. The company also terminated the employment of Brendan Hoffman as CEO.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:24 am

IMVT

Immunovant reported Q1 losses of $(0.57) per share, missing the analyst consensus estimate of $(0.45) by 26.67%. This is a 62.86% decrease over losses of $(0.35) per share from the same period last year. The company's cash and cash equivalents of $330M is expected to fund operations into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:22 am

MKTW

Marketwise reported Q2 sales of $103.60 million, missing the analyst consensus estimate of $109.32 million by 5.23 percent. This represents a 19.07 percent decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:20 am

CGEM

Cullinan Oncology reported Q2 losses of $(0.82) per share, a 121.75% decrease from the same period last year. However, the company's cash and investment position of $512.1M is expected to provide runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:19 am

ALYA

Alithya Group (NASDAQ:ALYA) reported Q1 earnings of $0.01 per share, beating the analyst consensus estimate of $(0.01) by 250 percent. However, the company's quarterly sales of $97.96 million missed the analyst consensus estimate of $104.69 million by 6.43 percent.

Portfolio Pulse from totan@benzinga.com

August 10, 2023 | 11:16 am

CYBR

CyberArk has released its 3Q23 revenue expectations, predicting a range of $181.5M-$186.5M, which is below the consensus of $187.14M. However, the company's adjusted EPS is expected to be between $0.19-$0.27, surpassing the consensus of $0.15. This represents a growth of 19-22% compared to the third quarter of 2022.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:14 am

ALYA

Alithya Group reported Q1 earnings of $0.02 per share, beating the analyst consensus estimate of $(0.03) by 166.67%. However, the company's quarterly sales of $131.59 million missed the analyst consensus estimate of $138.61 million by 5.06%. This represents a 3.81% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 10, 2023 | 11:14 am

RBLX

Roblox Corp (RBLX) reported Q2 FY23 bookings growth of 22% YoY to $780.7 million, and revenue growth of 15% YoY to $680.8 million, missing the consensus of $784.9 million. The EPS loss of $(0.46) also missed the consensus loss of $(0.45). Following the earnings announcement, Morgan Stanley raised the price target on Roblox from $26 to $30 and upgraded the stock from Underweight to Equal-Weight, while Needham slashed the price target from $48 to $40 but maintained a Buy rating.

Portfolio Pulse from Lisa Levin

August 10, 2023 | 11:13 am